证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-07 | --- | --- | --- | |----------|-------------------------------------------------------|-----------------------------------------------------------------------------------| | | | | | 投资者关 | □ 特定对象调研 | □ 分析师会议 | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | 其他 （电话会议） | | | 参与单位 | | 本次电话会议由西部证券组织召开，投资者名单由西部证券提供， | | 名称及人 | 包括锐智资本 娄 | 琦、明世伙伴 许庆华、明世伙伴 黄鹏、泰旸资 | | 员姓名 | 产 袁明懿、中信另类 磐泽资产 熊威明、国联安基金 | 罗啦、于翼资产 张亚辉、常春藤 石海慧、 黄欣、国泰基金 姜英、观富 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-08 | --- | --- | --- | |----------|---------------------------------------------------------------|--------------------------------------------------------------| | | | | | 投资者关 | 特定对象调研 | □ 分析师会议 | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | 其他 （电话会议） | | | 参与单位 | | 参加国金证券、光大证券组织的线上策略会，投资者名单由国金证券 | | 名称及人 | | 和光大证券提供，包括嘉实基金、睿郡资产、华宝兴业、新华资管、 | | 员姓名 | | 淡水泉、建信养老、东方证券自营、南方基金、前海开源基金、太平 | | | | 资产、景顺长城基金、健顺投资、安信基金、同犇投资、利幄、杭州 | | | ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-11 | --- | --- | --- | |----------|---------------------------------------------|-------------------------------------------------------------------------------------------| | | | | | 投资者关 | 特定对象调研 | □ 分析师会议 | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | | | | | | 其他 （天风证券策略会、德邦证券策略会、长江证券策略会） | | 参与单位 | | 参加天风证券策略会、德邦证券策略会、长江证券策略会，面向天风 | | 名称及人 | | 证券、德邦证券、长江证券邀请的投资者，包括嘉实基金 程佳、华 | | 员姓名 | 泰柏瑞 邹丽晴、富国基金 | 彭陈晨、睿亿投资 许峰、兴业证券自营 | | | ...

1 证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-12 | --- | --- | --- | |----------|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关 | □ 特定对象调研 | □ 分析师会议 | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | | | | | | 其他 （华创证券策略会、民生证券策略会、兴业证券策略会） | | 参与单位 | | 参加华创证券策略会、民生证券策略会、兴业证券策略会，面向华创 | | 名称及人 | | 证券、民生证券、兴业证 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-15 | --- | --- | --- | --- | --- | --- | --- | |--------------|---------------------------|-------|-----------------------|----------------------------------------------------------|----------------|-----------| | | | | | | | | | 投资者关系活 | □ 特定对象调研 | | □ 分析师会议 | | | | | 动类别 | □ | | | 媒体采访 □业绩说明会 | | | | | □ 新闻发布会 | | □路演活动 | | | | | | □ 现场参观 | | | | | | | | 其他 | | | | | | | 参与单位名称 | | | | 通过深圳市全景网络有限公司"全景路演"平台参加由青岛证监 | | | | 及人员姓名 | | | | 局、中证中小投资者服务中心有限责 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-14 | --- | --- | --- | |-------------------|--------------------------------|--------------------------------------------------------------| | | | | | 投资者关 | □ 特定对象调研 | □ 分析师会议 | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | 别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | | | | | | 其他 （天风证券策略会、国金证券策略会） | | 参与单位 | | 参加国金证券策略会、天风证券策略会，面向国金证券、天风证券邀 | | 名称及人 | 请的投资者，包括青骊投资 | 罗晓梅、弘尚资产 徐东、海富通基金 高 | | 员姓名 | 通、睿扬投资 | 王世超、鑫巢资本 王璞、上海古木投资 杨捷、华夏 | | | 基金 周天翎、华夏基金 | 常黎曼等。 | | 时间 | 2022 年 ...

证券代码：300143 证券简称：盈康生命 盈康生命科技股份有限公司 投资者关系活动记录表 编号：2022-13 | --- | --- | --- | --- | |----------|-------------------------------|--------------|--------------------------------------------------------------| | | | | | | 投资者关 | □ 特定对象调研 | □ 分析师会议 | | | 系活动类 | □ 媒体采访 | □ 业绩说明会 | | | 别 | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | 其他 （电话会议） | | | | 参与单位 | | | 本次电话会议由华安证券、天风证券、开源证券、东方证券、国金证 | | 名称及人 | | | 券、平安证券、中信建投证券、民生证券、东吴证券、兴业证券、西 | | 员姓名 | | | 部证券、华创证券联合举办，深圳进门财经科技股份有限公司承办。 | | | | | 投资者名单由深圳进门财经科技股份有限公司提供，详见 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥288,397,064.62, a decrease of 7.47% compared to the same period last year[4] - Net profit attributable to shareholders was ¥8,222,386.97, down 90.42% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥7,174,536.21, a decrease of 35.30% compared to the previous year[5] - The total revenue from January to the end of the reporting period reached ¥863,267,487.99, representing a year-on-year increase of 1.89%[9] - Total operating revenue for Q3 2022 was CNY 863,267,487.99, an increase of 1.23% compared to CNY 847,225,198.86 in Q3 2021[40] - Net profit for Q3 2022 was CNY 58,723,165.77, a decrease of 56.6% compared to CNY 135,459,716.41 in Q3 2021[42] - Earnings per share (EPS) for Q3 2022 was CNY 0.0864, down from CNY 0.1989 in the same period last year[42] - The company reported a total comprehensive income of CNY 60,551,313.97 for Q3 2022, compared to CNY 135,314,787.34 in Q3 2021, indicating a decline of about 55.2%[42] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥100,962,289.92, a decrease of 21.50% compared to the previous year[5] - Cash flow from operating activities was CNY 885,308,837.45, slightly up from CNY 881,322,208.28 in Q3 2021[43] - Cash and cash equivalents decreased to approximately RMB 423.81 million from RMB 661.55 million at the beginning of the year, representing a decline of about 36%[33] - The net cash flow from operating activities for Q3 2022 was ¥100,962,289.92, a decrease of 21.5% compared to ¥128,608,255.69 in Q3 2021[45] - Cash and cash equivalents at the end of the period stood at ¥423,805,700.69, down from ¥854,124,704.00 at the end of Q3 2021[47] - The net increase in cash and cash equivalents was -¥237,748,537.92, contrasting with an increase of ¥337,366,786.12 in Q3 2021[47] Research and Development - The company launched 78 new technologies in Q3, focusing on tumor treatment and enhancing service quality[9] - The company introduced a new external shortwave therapy device as part of its product development strategy[10] - Research and development expenses decreased significantly to CNY 13,500,225.66 from CNY 21,062,790.69, a reduction of approximately 35.8%[40] User Engagement and Services - The company achieved a significant increase in online users, with 116,000 new users added in Q3, representing a 207% year-over-year growth, and online revenue doubled compared to Q2[17] - In Q3, the company served 9,000 users for tumor early screening, and over 150,000 outpatient health check-ups were conducted[18] - The company’s digital medical services reached 70% of total users in Q3, excluding nucleic acid testing[19] Strategic Initiatives - The company established a strategic cooperation with Shanghai Tongshu Biotechnology for tumor special inspection projects, which has already been implemented at Sichuan Friendship Hospital[16] - The company participated in drafting the first national standard for radiation therapy centers, aiming to standardize construction and safety protocols in the industry[9] - The company has formed a joint working group for DRG payment reform, ensuring no medical insurance rejections at hospitals implementing DRG policies in Q3[20] - The company has partnered with Chengdu Medical College to enhance talent development and hospital management[24] - The company aims to improve its market competitiveness and position by establishing medical centers in five major economic zones[29] Financial Position - As of September 30, 2022, the company's total assets amounted to approximately RMB 2.43 billion, a decrease from RMB 2.47 billion at the beginning of the year[33] - The total assets of the company were CNY 2,430,197,826.98, down from CNY 2,473,064,924.99 in the previous year[39] - The company's goodwill increased to approximately RMB 1.03 billion from RMB 1.03 billion, showing a slight increase[35] - The total liabilities decreased to CNY 556,790,587.31 from CNY 667,566,060.72 year-over-year, reflecting a reduction of approximately 16.6%[39] - Total equity attributable to shareholders increased to CNY 1,836,023,710.38 from CNY 1,773,580,427.79, marking a growth of about 3.5%[39] Inventory and Receivables - Accounts receivable increased to approximately RMB 196.12 million, up from RMB 154.97 million, indicating a growth of about 27%[33] - The company reported an increase in inventory to approximately RMB 47.09 million from RMB 38.73 million, reflecting a growth of about 22%[35] Funding and Capital Structure - The company plans to issue A-shares to specific investors at a price of RMB 8.99 per share, aiming to raise up to RMB 1 billion to enhance its capital structure and support business development[31] - The company has recognized the need for additional funding to better seize industry development opportunities and mitigate risks[29] Operational Efficiency - The company's drug centralized revenue rate reached 34% and consumable centralized revenue rate reached 32% in Q3[25] - The clinical pathway admission rate reached 59.6% in Q3, exceeding the national standard of 50%[24] - The company has established a unified supply chain operation system for centralized management of drugs, consumables, and equipment[25] Audit and Compliance - The company has changed its auditing firm to enhance the independence and objectivity of its audit process[32]

Financial Performance - The company reported a total revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15% compared to the same period in 2021[22]. - The net profit attributable to shareholders was 50 million RMB, which is a 20% increase from the previous year[22]. - The company's operating revenue for the reporting period was ¥574,870,423.37, representing a 7.34% increase compared to the adjusted revenue of ¥535,552,059.89 from the same period last year[30]. - The net profit attributable to shareholders was ¥47,289,785.76, which is a 13.71% increase from the adjusted net profit of ¥41,589,655.89 in the previous year[30]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,052,785.31, a significant increase of 715.34% compared to the previous year's loss of ¥7,321,562.44[30][31]. - The company achieved total revenue of ¥574,870,423.37, a year-on-year increase of 7.34%, and a net profit of ¥49,814,728.37, up 5.58% year-on-year[65]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,052,785.31, reflecting a significant year-on-year increase of 715.34%[65]. User Growth and Market Expansion - User data showed an increase in active users by 25%, reaching a total of 1.5 million users by the end of June 2022[22]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[22]. - Online user growth reached 330,000, a 153% increase quarter-on-quarter, with online consultation rates up 204% and online prescription rates up 305%[71]. - The online user base accounted for 39% of total users (excluding nucleic acid testing) during the reporting period[75]. Product Development and Innovation - The company plans to launch two new medical devices in Q4 2022, aiming to capture a larger market share in the medical technology sector[22]. - Research and development expenses increased by 10% to 30 million RMB, reflecting the company's commitment to innovation[22]. - The company is focused on building a comprehensive solution for cancer treatment and rehabilitation, leveraging IoT medical technology and enhancing user experience through innovative services[41]. - The company is committed to a user-centered approach, integrating product innovation with clinical needs to enhance the overall healthcare experience[47]. - The company is focusing on the development of new products, including linear accelerators, to enhance its medical equipment segment[130]. Acquisitions and Mergers - The company completed the acquisition of 100% equity in Suzhou Guangci, which has been integrated as a wholly-owned subsidiary, leading to adjustments in financial reporting[30]. - The company has acquired Hebei Ailikesen Medical Technology Co., enhancing its product line with the registration and production license for an external shortwave therapy device[44]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market presence[22]. - The company is exploring mergers and acquisitions for outpatient hospitals to expand its market presence[131]. Financial Management and Investments - The net cash flow from operating activities decreased by 69.08% to ¥31,828,654.91, primarily due to increased payments for goods and services and delays in medical insurance reimbursements[31]. - The company reported a net cash flow from financing activities of -¥12,738,707.63, a 93.13% decrease compared to -¥185,350,906.36 in the previous year[80]. - The company reported a significant investment of ¥30,000,000.00 during the reporting period, a 37,400% increase compared to ¥80,000.00 in the same period last year[94]. - The total amount of raised funds was ¥72,788.82 million, with ¥406.09 million utilized during the reporting period, and a cumulative total of ¥68,715.34 million used[99]. Risk Management - The company has identified key risks including regulatory changes and market competition, and is implementing strategies to mitigate these risks[6]. - The company is actively managing industry risks related to medical policies that may affect market expansion[124]. - The company continues to enhance its management capabilities and expand its product line to mitigate operational risks from policy changes[124]. - The company is focusing on expanding its industrial chain around tumor pre-diagnosis, treatment, and health management to mitigate risks from international trade tensions and pandemic impacts on global economic development[125]. Environmental and Social Responsibility - The company emphasizes environmental protection as a key component of its sustainable development strategy, integrating green practices into operations[152]. - The company has developed a comprehensive medical waste management system to prevent pollution[152]. - During the reporting period, the company participated in 4,951 instances of volunteer work for pandemic response, completing over 3.38 million nucleic acid tests[153]. - The company conducted community medical services reaching nearly 30,000 people through various health campaigns[153]. Corporate Governance and Compliance - The company has not reported any changes in the use of raised funds during the reporting period[107]. - The semi-annual financial report has not been audited[169]. - There are no major litigation or arbitration matters during the reporting period[173]. - The company has not engaged in any bankruptcy reorganization during the reporting period[172].

Financial Performance - The company's operating revenue for 2021 was ¥1,089,867,456.38, representing a 5.93% increase from ¥1,028,881,713.89 in 2020[23]. - The net profit attributable to shareholders was -¥364,080,340.52, a decrease of 345.13% compared to ¥148,524,863.26 in 2020[23]. - The net cash flow from operating activities increased by 48.19% to ¥125,613,690.73 from ¥84,765,530.53 in 2020[23]. - The total assets at the end of 2021 were ¥2,473,064,924.99, a decrease of 20.82% from ¥3,123,256,096.67 in 2019[24]. - The net assets attributable to shareholders decreased by 31.70% to ¥1,773,580,427.79 from ¥2,596,566,542.26 in 2019[24]. - The diluted earnings per share for 2021 was -¥0.57, a decline of 328.00% from ¥0.25 in 2020[24]. - The company achieved total revenue of ¥1,089,867,456.38, representing a year-on-year growth of 5.93%[74]. - The net profit attributable to shareholders was -¥364,080,340.52, a year-on-year decline of 345.13%[74]. - The company's operating costs rose to ¥828,999,352.44, a year-on-year increase of 11.09%, mainly due to increased epidemic prevention costs, labor costs, and daily operational costs[85]. Research and Development - The total R&D investment for the reporting period was 28.86 million yuan, an increase of 62.03% compared to 17.81 million yuan in the same period last year[6]. - The company has established a 1+5 organizational network for its R&D system, enhancing its capacity for product innovation and development[59]. - The company launched 86 new technologies in the oncology field and introduced over 200 new devices/products during the reporting period[74]. - R&D expenses rose by 69.81% to approximately ¥28.86 million, reflecting increased investment in research and development[99]. - The number of R&D personnel increased by 27.78% to 46, with a 55% increase in personnel holding a bachelor's degree[103]. - R&D investment amounted to approximately ¥28.86 million, representing 2.65% of operating revenue, up from 1.73% the previous year[106]. Market and Industry Trends - The population aged 60 and above in China reached 267.36 million in 2021, accounting for 18.9% of the total population, an increase of 0.7 percentage points from 2020[39]. - The number of cancer patients in China is projected to increase significantly, with 4.57 million new cases reported in 2020, representing 23.7% of the global total[50]. - The domestic cancer medical service market was valued at ¥371.1 billion in 2019 and is expected to grow to ¥700.3 billion by 2025, with a compound annual growth rate (CAGR) of 12.5%[52]. - The utilization rate of radiotherapy for cancer patients in China is only 20%-30%, compared to approximately 70% in the United States, indicating significant market potential[53]. - The company anticipates that the private hospital market will expand from ¥34.4 billion in 2019 to ¥102.3 billion by 2025, with a CAGR of 19.9%[52]. - The average per capita healthcare expenditure in China has been increasing, reflecting a growing awareness of health and wellness among residents[47]. Corporate Governance - All directors attended the board meeting to review the annual report, ensuring comprehensive oversight[4]. - The company is committed to maintaining high standards of corporate governance and transparency in its operations[191]. - The governance structure complies with relevant laws and regulations, ensuring no significant discrepancies with regulatory requirements[178]. - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring transparency in appointments[176]. - The independent directors provide objective opinions on significant matters, safeguarding the interests of minority shareholders[174]. - The company maintains independence from its controlling shareholder, with no instances of fund occupation or guarantee provision[171]. Strategic Initiatives - The company is focused on building an AIOT medical technology ecosystem centered around cancer treatment, integrating medical services and AIOT devices to enhance user experience[57]. - The company is leveraging digital healthcare services to improve operational efficiency and patient experience, allowing patients to receive top-tier cancer treatment without leaving their locality[68]. - The company aims to expand its service capabilities by extending its cancer service chain and enhancing its diagnostic and rehabilitation product offerings[67]. - The company is focusing on talent management by building a sustainable talent development platform and attracting top professionals through competitive incentive mechanisms[81]. - The company plans to leverage the financial capabilities and resources of its controlling shareholder to empower its development[145]. Acquisitions and Restructuring - The company completed the acquisition of 100% equity in Suzhou Guangci on November 18, 2021, leading to a significant asset restructuring[25]. - The company completed the acquisition of Suzhou Guangci Tumor Hospital for CNY 450,000,000, achieving a 100% equity stake[124]. - The company sold 100% equity of Changsha Yinkang Hospital for a transaction price of CNY 40.39 million, contributing a net profit of CNY -4.77 million before the sale, which accounted for 6.19% of the total net profit[140]. - The company sold 100% equity of Changchun Yinkang Hospital for a transaction price of CNY 52.18 million, contributing a net profit of CNY -15.93 million before the sale, which accounted for 7.03% of the total net profit[140]. - The company established a new subsidiary, Xingmakang Medical Technology, with a registered capital of CNY 50 million to enhance its supply chain platform and expand medical service ecosystem revenue[145]. Financial Management - The company has not encountered any significant changes in project feasibility or delays in expected benefits[134]. - The company has not reported any changes in the use of raised funds or any issues in the disclosure of fund usage[136]. - The company reported a total of CNY 1,300,260,000 in structured deposits purchased during the period, with a return of CNY 11,477,619.62 from these investments[127]. - The company utilized CNY 649.35 million of the raised funds during the reporting period, with a total cumulative usage of CNY 68,309.25 million[131]. - The company reported a significant proportion of revenue from oncology services at Sichuan Friendship Hospital[161]. Risks and Challenges - The company faces industry risks related to changes in medical policies affecting large medical equipment, which could impact market expansion[156]. - The company is also exposed to macroeconomic risks, including potential impacts from international trade tensions and ongoing pandemic effects on global economic development[156]. - The company has significant goodwill from acquisitions, and any underperformance of acquired entities could lead to goodwill impairment risks[156]. Shareholder Engagement - The company held 5 shareholder meetings during the reporting period, utilizing a combination of online and on-site voting to facilitate participation[170]. - The first temporary shareholders' meeting in 2021 had an investor participation rate of 7.43% on February 23, 2021[183]. - The annual shareholders' meeting in 2020 had a participation rate of 44.55% on May 20, 2021[183]. - The company has signed a management agreement with Friendship Hospital to manage several hospitals, reducing competition with its actual controller[180].